Tissue Removal During Hysterectomy: The Effect of Vaginal Versus Abdominal Morcellation on Surgical Outcomes

Fibroids Clinical Trial

Official title:

Tissue Removal During Hysterectomy: The Effect of Vaginal Versus Abdominal Morcellation on Surgical Outcomes

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02703246
• Other study ID #: 091553
• Status: Withdrawn
• Phase: N/A
• Start date: January 2016
• Est. completion date: May 2023

Study information

• Verified date: June 2023
• Source: George Washington University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In this study the investigators will perform a randomized trial to compare the surgical outcomes of vaginal versus abdominal morcellation of the uterus during hysterectomy. In minimally invasive gynecologic surgery small incisions are made in the abdomen and pelvis so that a hysterectomy can be performed by laparoscopy. The challenge is then to remove the uterus, which may be quite large, through these small incisions. One option is to morcellate the uterus and remove the tissue through either a small abdominal incision or an incision in the vagina. When an organ is morcellated it is cut into smaller pieces so that it can be removed, section by section, through a small incision. The investigators will compare these two methods of tissue removal to see whether one results in better surgical outcomes or increased intra-operative or post-operative complications. The primary outcome will be the time it takes to perform the surgery (operative time). Secondary surgical outcomes that will be studied include the amount of blood lost during surgery, post-operative complications, and readmission to the hospital.

Description:

Hysterectomy is the most commonly performed non-obstetric procedure in women in the United States, with approximately 400,000 hysterectomies performed each year. Minimally invasive techniques have all been shown to have advantages over laparotomy. These include decreased blood loss, faster recovery time, improved postoperative pain and decreased postoperative complications including wound infections, thromboembolism, iatrogenic injuries and incisional hernias. Due to all of these benefits, the volume of minimally invasive procedures has increased significantly over the last ten years making tissue extraction a widely debated topic.

Morcellation is a technique that allows large pieces of tissue to be removed through small incisions and was originally performed either with a scalpel or manual device until the first power/electric morcellators were introduced in 1993. Since then, power morcellation has made 50,000 to 150,000 minimally invasive hysterectomies possible annually. While the former has been an integral part in the treatment of women with large uteri and uterine fibroids, it has recently come under scrutiny due to multiple concerns including dissemination of undetected malignancy, development of iatrogenic myomas as well as increased number of reported complications and death. This has led the US Food and drug administration in April 2014 to issue a statement discouraging the use of laparoscopic power morcellation.

In the face of the growing bias against electronic mechanical morcellators, other approaches must be investigated and promulgated so that patients may still benefit from minimally invasive gynecologic surgeries. The two commonly used methods for tissue extraction are manual morcellation through mini-laparotomy and vaginal morcellation. In the former, a trocar site enlargement or a new up to 1 inch incision is created through which the specimen is brought to the abdominal surface and morcellated with scalpel.In the latter, tissues are removed in the same fashion but via a colpotomy. The investigators intent is to compare manual morcellation methods (vaginal vs abdominal mini-laparotomy) in order to help surgeons choose the best approach for their patient.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: May 2023
• Est. primary completion date: May 2023
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Hysterectomy planned for a benign gynecologic reason

• Patient is scheduled to have surgery with one of the minimally invasive gynecologic surgeons at George Washington University Hospital. (Dr. Moawad, Dr. Marfori, or Dr. Vargas)

• Patient is planned for a robotic assisted total laparoscopic hysterectomy (RA-TLH) or a total laparoscopic hysterectomy (TLH)

• Patient is capable of informed consent

• Patient must be between 18 and 65 years of age

• Uterus greater than 12 centimeters in height and 4 centimeters in width or 12 weeks in size

Exclusion Criteria:

• Hysterectomy is indicated for malignancy

• Procedure is anything other than RA-TLH or TLH

• Surgeon is not one of hte minimally invasive surgeons at GWUH

• Surgery is scheduled for a hospital other than GWUH

• Patient does not meet the age requirements.

• Patient is not capable of informed consent

• Uterus is less than 12 cm in heightand 4 cm in width

Related Conditions & MeSH terms

• Fibroids
• Leiomyoma

Intervention

Procedure:
• abdominal morcellation
patients will be randomized to receive abdominal morcellation
• vaginal morcellation
patients will be randomized to receive vaginal morcellation

Locations

Country	Name	City	State
United States	George Washington University Medical Faculty Associates	Washington	District of Columbia

Sponsors (1)

Lead Sponsor	Collaborator
George Washington University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Total operative time	Time (in minutes) from when first cut is made until last suture is made.	Perioperative
Secondary	Blood Loss	as measured in cubic centimeters (cc)	perioperative
Secondary	Intraoperative complications	Intraoperative complications include: Organ injury (bladder, bowel, vaginal laceration), Estimated Blood Loss>1000cc, and conversion to laparotomy	perioperative
Secondary	Post-operative complications	Post-operative complications include: Reoperation, Intensive Care Unit (ICU) admission, Deep Vein Thrombosis/Pulmonary Embolism (DVT/PE), transfusion, Readmission, Bowel obstruction/ileus, Incision seroma/cellulitis/hematoma/separation/hernia, and cuff cellulitis/abcess/dehiscence/granulation tissue	as recorded between end of operation and 4 weeks post operation